Author Archives: Ben Comer
By Ben Comer | Published: June 5, 2013
Dr. Richard Gliklich, president of Quintiles Outcome and a professor at Harvard Medical School, highlights the most prominent post-approval issues and risks coming out of this year’s Post-Approval Summit, held on May 7th-8th. Brand managers prodding products across the regulatory finish line to commercialization are finding themselves in yet another race, instead of in [...]
By Ben Comer | Published: May 17, 2013
US-based Bayer Healthcare Pharmaceuticals, as its executives were quick to point out, has now received three new approvals for cancer indications in the last eight months.
By Ben Comer | Published: May 7, 2013
During the Rutgers Business School’s annual healthcare symposium, an FDA official encouraged industry to put its drugs on the reviewing table and be prepared for good news. On a panel titled “Activist FDA: Transformation Agent,” Prevision Policy founder and former Pink Sheet editorial head Cole Werble relayed the tale of Acadia Pharmaceuticals, a San Diego-based [...]
By Ben Comer | Published: April 16, 2013
People tell you who they are, but we ignore it – because we want them to be who we want them to be. – Don Draper At the beginning of the Reboot Camp – held at New York City’s Alexandria Center on April 12 – Intouch Solutions’ CEO Faruk Capan declared the days of Don Draper [...]
By Ben Comer | Published: April 4, 2013
Cash-strapped states are shifting patients from traditional fee-for-service Medicaid coverage to managed Medicaid plans. The IMS Institute of Healthcare Informatics took an early look at how this trend effects prescription drug utilization.